PRAME is altered in 1.91% of malignant solid tumor patients [3].

PRAME is an inclusion criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain PRAME status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

PRAME is altered in 2.09% of acute myeloid leukemia patients [3].

PRAME is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains PRAME status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PRAME is altered in 1.49% of ovarian carcinoma patients [3].

PRAME is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PRAME status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PRAME is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-1, of which 1 is open and 0 are closed. Of the trial that contains PRAME status and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PRAME is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains PRAME status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].